Advertisement

PET/CT in Adrenal Glands

  • Alexandra V. Nikaki
Chapter

Abstract

Adrenal glands serve as potential sites for secondary infiltration of various cancers. Moreover, primary tumors can arise, either from the cortex or from the medulla of the glands. Single photon emitters with g-camera procedures have long been used for evaluation of primary tumors with high sensitivity and specificity. F-18–FDG-PET/CT has mostly been evaluated as a diagnostic tool in detection of adrenal metastasis, while other positron radiopharmaceuticals have been used for the identification and evaluation of disease extent in primary adrenal tumors.

References

  1. 1.
    Tessonnier L, Sebag F, Palazzo FF et al (2008) Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging 35(11):2018–2025CrossRefGoogle Scholar
  2. 2.
    Jana S, Zhang T, Milstein DM et al (2006) FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 33(1):29–35CrossRefGoogle Scholar
  3. 3.
    Boland GW, Dwamena BA, Jagtiani Sangwaiya M et al (2011) Characterization of adrenal masses by using FDG PET: a systematic review and meta- analysis of diagnostic test performance. Radiology 259(1):117–126CrossRefGoogle Scholar
  4. 4.
    Ozcan Kara P, Kara T, Kara Gedik G et al (2011) The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 32(2):106–112CrossRefGoogle Scholar
  5. 5.
    Xu B, Gao J, Cui L et al (2012) Characterization of adrenal metastatic cancer using FDG PET/CT. Neoplasma 59(1):92–99CrossRefGoogle Scholar
  6. 6.
    Terzolo M, Stigliano A, Chiodini I et al (2011) AME position statement on adrenal incidentaloma. Eur J Endocrinol 164:851–870CrossRefGoogle Scholar
  7. 7.
    Perri M, Erba P, Volterrani D et al (2011) Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol 197(1):209–216CrossRefGoogle Scholar
  8. 8.
    Ansquer C, Scigliano S, Mirallié E et al (2010) 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging 37(9):16691678CrossRefGoogle Scholar
  9. 9.
    Kunikowska J, Matyskiel R, Toutounchi S et al (2014) What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions? Eur J Nucl Med Mol Imaging 41(12):2273–2280CrossRefGoogle Scholar
  10. 10.
    Boland GW, Blake MA, Holalkere NS, Hahn PF (2009) PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR 192(4):956–962CrossRefGoogle Scholar
  11. 11.
    Koopman D, van Dalen JA, Stigt JA et al (2016) Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands. Ann Nucl Med 30:145–152CrossRefGoogle Scholar
  12. 12.
    Stone WZ, Wymer DC, Canales BK (2014) Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm. J Endourol 28(1):104–111CrossRefGoogle Scholar
  13. 13.
    Havekes B, Kathryn King K, Edwin W, Lai EW et al (2010) New imaging approaches to pheochro-mocytomas and paragangliomas. Clin Endocrinol 72(2):137–145CrossRefGoogle Scholar
  14. 14.
    Rufini V, Treglia G, Castaldi P et al (2011) Comparison of 123I-MIBG SPECT-CT and 18F- DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 32(7):575–582CrossRefGoogle Scholar
  15. 15.
    Rischke HC, Benz MR, Wild D et al (2012) Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. J Nucl Med 53(9):1352–1358CrossRefGoogle Scholar
  16. 16.
    Heimburger C, Veillon F, Taïeb D et al (2017) Head-to-head comparison between 18F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas. Eur J Nucl Med Mol Imaging 44(6):979–987.  https://doi.org/10.1007/s00259-016-3605-0 CrossRefPubMedGoogle Scholar
  17. 17.
    Naswa N, Sharma P, Nazar AH et al (2012) Prospective evaluation of 68Ga-DOTA-NOC PET- CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol 22(3):710–719CrossRefGoogle Scholar
  18. 18.
    Maurice JB, Troke R, Win Z et al (2012) A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39(8):1266–1270CrossRefGoogle Scholar
  19. 19.
    Timmers HJ, Kozupa A, Chen CC et al (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25(16):2262–2269CrossRefGoogle Scholar
  20. 20.
    Timmers HJ, Chen CC, Carrasquillo JA et al (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 104(9):700–708CrossRefGoogle Scholar
  21. 21.
    Hennings J, Lindhe O, Bergström M et al (2006) [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91(4):1410–1414CrossRefGoogle Scholar
  22. 22.
    Hennings J, Sundin A, Hägg A, Hellman P (2010) 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbeck's Arch Surg 395(7):963–967CrossRefGoogle Scholar
  23. 23.
    Hennings J, Hellman P, Ahlström H, Sundin A (2009) Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 69(2):314–323CrossRefGoogle Scholar
  24. 24.
    Razifar P, Hennings J, Monazzam A et al (2009) Masked volume wise principal component analysis of small adrenocortical tumours in dynamic [11C]-metomidate positron emission tomography. BMC Med Imaging 22(9):6CrossRefGoogle Scholar
  25. 25.
    Khan TS, Sundin A, Juhlin C et al (2003) 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30(3):403–410CrossRefGoogle Scholar
  26. 26.
    Leboulleux S, Dromain C, Bonniaud G et al (2006) Diagnostic and prognostic value of 18- fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91(3):920–925CrossRefGoogle Scholar
  27. 27.
    Tessonnier L, Ansquer C, Bournaud C et al (2013) 18F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value. World J Surg 37(1):107–112CrossRefGoogle Scholar
  28. 28.
    Boubaker A, Bischof Delaloye A (2003) Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med 47(1):31–40PubMedGoogle Scholar
  29. 29.
    Chawla M, Kumar R, Sandeep A et al (2010) Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastoma. Indian J Nucl Med 25(4):147–155PubMedPubMedCentralGoogle Scholar
  30. 30.
    Papathanasiou ND, Gaze MN, Sullivan K et al (2011) 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med 52(4):519–525CrossRefGoogle Scholar
  31. 31.
    Piccardo A, Lopci E, Conte M et al (2012) Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 39(1):57–71CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Alexandra V. Nikaki
    • 1
    • 2
  1. 1.Department of Clinical PhysiologyKanta-Hame Central HospitalHameenlinnaFinland
  2. 2.Department of Nuclear Medicine and PET/CTHygeia HospitalAthensGreece

Personalised recommendations